Vertex Pharmaceuticals Incorporated (VRTX) : During the past 4 weeks, traders have been relatively bearish on Vertex Pharmaceuticals Incorporated (VRTX), hence the stock is down -0.34% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.09% relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.41% in the last 1 week, and is up 4.01% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 3.85% and the 50-Day Moving Average is 2.91%.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $89.34 and $88.05 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $90.86. The buying momentum continued till the end and the stock did not give up its gains. It closed at $90.21, notching a gain of 2.34% for the day. The total traded volume was 1,309,647 . The stock had closed at $88.15 on the previous day.
The company Insiders own 1.8% of Vertex Pharmaceuticals Incorporated shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.03% . Institutional Investors own 97.08% of Vertex Pharmaceuticals Incorporated shares. During last six month period, the net percent change held by insiders has seen a change of -3.03%. In a related news, Boger Joshua S, director of Vertex Pharmaceuticals Inc / Ma, unloaded 6,500 shares at an average price of $89.07 on July 13, 2016. The total amount of the transaction was worth $578,955, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.